March 28, 2016 6:13pm
The selling pressure returns as the month and quarter’s end is coming.
Ranking Monday’s end-of-day pre-open trading indications – 1 hit– a bold call, Vericel (VCEL -$0.73) and 3 penny price misses
Subscribe: http://www.regmedinvestors.com/create-account
There is one thing that everyone needs, and that's interpretation and translation of intelligence, not just news or information - we get too much!
- To that end, I report a matrix of variables designed for investor’s consideration concerning the stem, cell and gene therapy regenerative medicine portfolio to track and monitor its pricing metric;
The takeaway is that investor need to decide what actions to take, or not take, based on their specific situation.
U.S. stocks closed mixed Monday in low volume trade as investors eyed oil prices and awaited data and comments from key Fed policymakers due later in the week.
The NASDAQ closed DOWN -6.72 or -0.14% to 4,766.79 and the DOW closed UP +19.66 or +0.11% to 17,535.39.
A day in the life of the stem, cell and gene therapy RegMed (SCGT & RM) sector – the advance/decline line scenario of our 43 covered companies.
- Monday, the stem, cell and gene therapy and regenerative medicine sector opened negative with an A/DL of 12/25 and 6 flats;
- The mid-day continued negative with an A/DL of 13/27 and 3 flats;
- The closing bell rang NEGATIVE with A/DL of 9/32 and 2 flats
Earnings update:
- Regenerative Medicine Earnings Scorecard - Q4/2015 - to date … http://www.regmedinvestors.com/articles/8876
Henry’omics:
The stem, cell and gene therapy regenerative medicine (SCGT&RM) sector opened negative, stayed negative at the mid-day and closed … negative (of 43 covered companies).
- The end of the month and quarter is ending – after all the “runs”, it was a traders delight to time the sell!
The iShares Biotechnology Stocks ETF (IBB) closed DOWN on Monday -3.40 or -1.33%
- Also, a reminder from my Thursday’s closing post …”I think right now we're in the “pull and push” mode. There's a lot of profit-taking, end-of-month and end-of-quarter trading!” Is there a finger on the trigger?
I “felt’ it was coming, as I stated in the pre-open post – don’t fight the tape. Not fighting doesn’t necessarily mean what it seems, it depends on how “our” universe is trading.
- Volatility is also back and will likely remain for at least the next few months. As we came into this week, I warned that trading room would act with more than a certain amount of whipsaw.
As I stated last Thursday, it’s a trading market and NOT sustainable to investors.
Monday’s handicapping the sector pre-open indications – 1 hits and 3 miss:
- Capricor (CAPR) closed UP +$0.12 – miss;
- Osiris (OSIR) closed DOWN -$0.02 – miss;
- Verastem (VSTM) closed DOWN -$0.03 – miss;
- Vericel (VCEL) closed DOWN -$0.73 – hit;
Dosing the sector – what a day for the 43 Patients:
- The market opened: NEGATIVE with 25 decliners, 12 advancers and 6 flats;
- The mid-day (12:30 pm: NEGATIVE with 27 decliners, 13 advancers and 3 flats;
- Closing bell: NEGATIVE with 32 decliners, 9 advancers and 2 flats
Review my fear gauge or the CBOE Volatility Index (VIX) which is scary:
- Monday traded near 15;
- Friday, market was closed;
- Thursday traded near 15.5;
- Wednesday traded below 15;
- Tuesday traded above 14;
- Last, Monday traded near 14;
Riding the indexes and ETFs roller-coaster:
The iShares Biotechnology Stocks ETF (IBB) closed DOWN on Monday -3.40 or -1.33%
- Friday – market closed;
- Thursday +1.19 or +0.47%
- Wednesday -8.84 or -3.36%
- Tuesday +6.61 or +2.58%
- Last, Monday +5.15 or +2.05%
The NASDAQ Biotechnology index (NBI) closed DOWN on Monday -34.73 or -1.30%
- Thursday +14.65 or +0.55%
- Wednesday -93.34 or -3.39%
- Tuesday +69.98 or +2.61%
- Last, Monday +50.02 or +1.90%
The Russell 2000 (IWM) closed UP on Monday +0.13 or +0.12%
- Friday – market closed;
- Thursday +0.32 or +0.30%
- Wednesday -2.01 or -1.85%
- Tuesday -0.13 or -0.12%
- Last, Monday -0.26 or -0.24%
The SPDR SD&P Biotech ETF (XBI) closed DOWN on Monday -0.65 or -1.30%
- Friday – market closed;
- Thursday +0.18 or +0.36%
- Wednesday -2.61 or -4.97%
- Tuesday +1.66 or +3.27%
- Last, Monday +1.18 or +2.38
Who was leading the declines – to of the bottom 5?
- Intrexon (XON) closed down -$1.41 to $34.53;
- Juno Therapeutics (JUNO) -$0.77 to $36.01;
- Vericel (VCEL) -$0.73 to $5.35;
- uniQure (QURE) -$0.47 to $11.48;
- Spark Therapeutics (ONCE) closed down -$0.46 to $31.97;
Who was UP – top 5:
- Kite Pharma (KITE) closed up +$1.12 to $43.49;
- bluebird bio (BLUE) +$0.39 to $39.78;
- International Stem Cell (ISCO) +$0.25 to $4.00;
- Opexa (OPXA) +$0.24 to $2.40;
- Asterias Biotherapeutics (NYSEMKT: AST) closed up +$0.10 to $4.67
Who was FLAT?
- ReNeuron (RENE.L) at $3.375;
- VistaGen (VSTA) at $8.00
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
